Quantum-si Incorporated · NASDAQ:QSI
Quantum-si — Investor Presentation (June 2021)
16 slides from Quantum-si's investor presentation, Jun 15, 2021
Slide 1: Quantum-Si Investor Presentation
Quantum - Si Investor Presentation
Slide 2: Forward-Looking Statements
Forward - Looking Statements This presentation includes “forward - looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results of Quantum - Si Incorporated (the “Company”) may differ from its expectation
Slide 3: Slide 3
Slide 4: What if we could understand how disease is progressing in real-time?
3 What if we could understand how disease is progressing in real - time and provide immediate guidance on personalized treatment?
Slide 5: Slide 5
Slide 6: The Next Transformation Anticipated in Life Sciences: Single Molecule Protein Sequencing
The Next Transformation Anticipated in Life Sciences: Single Molecule Protein Sequencing qPCR Sanger Mic r oarrays Mass Spec ELISA Genomics P r otein 2000s Analog Gene and Transcript Resolution Birth of Digital DNA Sequencing Analog Protein and Peptide Level Single Molecule, Benchtop Systems and Cli
Slide 7: Why is understanding the Proteome transformative?
Current State of Treatment 90 of Approved Drugs Target a Protein 1 Novel Therapies of proteome undrugged 2 Why is understanding the Proteome transformative? Proteins represents the clinical end point and uilding locks of life What is there? How much is there? How has it been changed? Patient Care 10
Slide 8: End-to-End Protein Analysis Platform
End - to - End Protein Analysis Platform Car on Universal sample preparation for both protein and A Platinum Single Molecule Analysis Cloud Secure data storage and analysis wor ows Sample Prep Sequencing Analysis
Slide 9: Potential Digital Disruption and Expansion of a $44B Market
1 2M Molecular tests performed each year in S Clinical Testing 20,000 Proteomics instrument Installations 1 ,000 Bench Top DNA Digital Sequencing Systems Potential Digital Disruption and Expansion of a $44B Market Quantitative Proteomics $ 1B 2020 CAGR Sequencing $ B 2020 CAGR $ B 2020 1 CAGR Pharma
Slide 10: Novel Biological Understanding: Next Frontier of Assessing Recurrence and Treatment
9 ovel Biological Understanding: ext Frontier of Assessing Recurrence and Treatment Phosphorylated Tyrosine T y r osine Post - translational Modiications Our technology detects post - translational modiications like any other amino acid We can currently recognize phosphorylated tyrosine on chip and
Slide 11: Delivering on what we believe the market demands
Mass Spec igital A Sequencing Single Molecule A Sequencing Quantum - Si Quantitative Analysis Protein Quantitative Analysis DNA Benchtop System Single Molecule And inally delivering on what we elieve the market demands
Slide 12: Well Positioned to Be a Leader in the Proteomics Revolution
Sample P r eparatio n Single Molecul e Analysis Platform* Protein Identiication Protein Quantitatio n Analysis Output Well Positioned to e a Leader in the Proteomics Revolution *Quantum - Si End to End Analysis Solution Controls the Entirety of the Workflow
Slide 13: Pathway for Growth and Customer Adoption
Pathway for Growth and Customer Adoption Drive Adoption Revenue Expand ser Base $1 M+ Revenue 2021 202 Develop New Applications Optimized Workflow and Data Analysis Scaled Production/Supply Chain irst Two Systems Shipped Q1, 2021 Early Access Develop Key Influencers Initial Launch Product pdates Por
Slide 14: Valuation Potential
3 aluation Potential • 200 launch • Leveraged foothold in the genomics market 201 launch Leveraged the uman Cell Atlas program and Illumina footprint • 2020 IPO • 2022 anticipated commercial launch 2 P r e - comme r cial B Mar et Cap Today B Mar et Cap Today B Mar et Cap Today Seer Illumina Revenues
Slide 15: Meet the Team
Meet the Team ONAT AN ROT BERG Executive Chai r man O N S T ARK Chief Executive Oficer CLA DIA DRA TON Chief inancial Oficer M A TT D ER Chief Business Oficer MIKE MCKENNA Chief Operations Oficer TODD REARICK Chief Technology Oficer C RISTIAN LAPOINTE General Counsel BRIAN REED ead of Resear ch AISA
Slide 16: Pioneering Next Generation Single Molecule Sequencing
• Commercializing single - molecule protein sequencing platform scaled y a irst of its kind semiconductor chip with over 0 1 issued and pending patents • Positioned for massive market expansion and to digitize a $44B 2 legacy proteomics research and diagnostic markets • Leveraging decades of advance